US · AVXL
Anavex Life Sciences Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10019
- Website
- anavex.com
Price · as of 2025-09-30
$3.32
Market cap 410.54M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $5.20 | ||||
| 2012 | $3.88 | ||||
| 2013 | $1.52 | ||||
| 2014 | $0.84 | ||||
| 2015 | $7.11 | ||||
| 2016 | $4.35 | ||||
| 2017 | $3.69 | ||||
| 2018 | $2.15 | ||||
| 2019 | $2.65 | ||||
| 2020 | $5.00 | ||||
| 2021 | $18.84 | ||||
| 2022 | $7.65 | ||||
| 2023 | $7.96 | ||||
| 2024 | $8.14 | ||||
| 2025 | $4.40 |
AI valuation
Our deep-learning model estimates Anavex Life Sciences Corp.'s (AVXL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.32
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AVXL | Anavex Life Sciences Corp… | $3.32 | 410.54M | — | — | — | — | -8.09 | 3.96 | — | -5.88 | -210.39 | 3.96 | 0.00% | — | — | -43.11% | 523.72% | -38.75% | 0.00 | — | 11.60 | 11.56 | 2.21 | 385.00% | — | 2672.00% | -10.40% | -4.36 | 397.76% | 0.00% | 0.00% | 0.00% | -5.30 | -6.98 | — | 19.47 |
| ABSI | Absci Corporation | $2.74 | 412.02M | +823% | -47% | — | +302% | -3.34 | 1.92 | 75.86 | -2.57 | — | 2.56 | -1277.57% | -2401.59% | -2274.06% | -58.04% | -127.20% | -47.86% | 0.06 | -192.72 | 4.67 | 3.92 | 0.33 | -2167.00% | -2071.00% | 1116.00% | -21.17% | -2.53 | -85.05% | 0.00% | 0.00% | 0.00% | -2.22 | -3.32 | 53.29 | 1.58 |
| ARVN | Arvinas, Inc. | $13.27 | 974.25M | +82% | -40% | -97% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| ATXS | Astria Therapeutics, Inc. | $12.58 | 718.13M | — | — | — | — | -3.69 | 1.09 | — | -0.26 | — | 1.09 | 0.00% | — | — | -33.52% | 3380.03% | -31.58% | 0.02 | — | 17.49 | 17.15 | 0.58 | -3058.00% | — | 1908.00% | -23.45% | -4.25 | 2470.44% | 0.00% | 0.00% | 0.00% | -0.22 | -0.30 | — | 6.30 |
| CTMX | CytomX Therapeutics, Inc. | $5.37 | 909.87M | +2,414% | -87% | -65% | +202% | 1.76 | -123.14 | 0.41 | -1.31 | — | -28.25 | 100.00% | 18.10% | 23.08% | -133.06% | -16.56% | 19.77% | -20.58 | — | 1.25 | 1.21 | -1.07 | -503506.00% | 3645.00% | 5216.00% | -154.12% | -1.01 | 57.76% | 0.00% | 0.00% | 45.36% | -1.40 | 0.41 | -0.25 | -5.71 |
| ERAS | Erasca, Inc. | $13.66 | 4.23B | — | — | — | — | -2.21 | 0.84 | — | -0.73 | — | 0.84 | 0.00% | — | — | -43.68% | -151.38% | -36.01% | 0.12 | — | 9.84 | 9.58 | 0.10 | -1687.00% | — | 2814.00% | -36.89% | -3.49 | -111.24% | 0.00% | 0.00% | 0.00% | -0.62 | -0.84 | — | 0.06 |
| MBX | MBX Biosciences, Inc. Com… | $32.55 | 1.09B | — | — | — | — | -5.33 | 1.28 | — | -1.00 | -6.55 | 1.28 | 0.00% | — | — | -66.95% | 86.67% | -35.11% | 0.00 | — | 24.19 | 23.78 | 0.72 | 8137.00% | — | 7303.00% | -16.82% | -4.95 | 70.61% | 0.00% | 0.00% | 5.75% | -1.00 | -1.23 | — | 17.45 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| VALN | Valneva SE | $11.09 | 954.23M | +215% | -66% | -82% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- CEO
- Christopher U. Missling
- Employees
- 42
- Beta
- 1.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.32) − 1 = — (DCF, example).